Pharmaceutical Industry Should Invest More In NTDs

In this Forbes opinion piece, contributor Sarika Bansal examines “[w]hat needs to happen for the pharmaceutical industry, academic researchers, and other key players [to] begin investing more seriously in” efforts to address neglected tropical diseases (NTDs). She writes, “Since the term [NTD] was coined [in 2005], there has been considerable activity in the neglected disease space from governments, donors, pharmaceutical companies, and nonprofits alike,” but the status quo “has not yet changed nearly enough, and there is ample room for the pharmaceutical industry to invest more in NTDs.”

Bansal highlights progress in the fight against NTDs, noting an increase in donor funding and product development and the establishment of product development partnerships (PDPs) for NTDs, such as PATH and the Sabin Vaccine Institute. She concludes, “Donor-funded PDPs will continue conducting vital research to end the disease burden of several common NTDs, with donations from pharmaceutical companies. … Hopefully these raised expectations … can soon compel pharmaceutical companies to directly develop drugs and vaccines for the world’s poorest billion” (11/9).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.